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Abstract
Psoriatic arthritis is a part of the family of diseases referred to as spondyloarthropathies, a diverse group of chronic
inflammatory disorders with common clinical, radiographic, and genetic features. Peripheral arthritis is the most
common symptom of psoriatic arthritis and patients also frequently experience involvement of the entheses, spine,
skin, and nails. Due to the diverse clinical spectrum of disease severity, tissues affected, and associated comorbidities,
the treatment of psoriatic arthritis can be challenging and it is necessary to mitigate risks associated with both the
disease and its treatment. These risks include disease-specific, treatment-related, and psychological risks. Disease-
specific risks include those associated with disease progression that can limit functional status and be mitigated
through early diagnosis and initiation of treatment. Risks also arise from comorbidities that are associated with psoriatic
arthritis such as cardiovascular disease, obesity, diabetes mellitus, and gastrointestinal inflammation. Patient outcomes
can be affected by the treatment strategy employed and the pharmacologic agents administered. Additionally, it is
important for physicians to be aware of risks specific to each therapeutic option. The impact of psoriatic arthritis is not
limited to the skin and joints and it is common for patients to experience quality-of-life impairment. Patients are also
more likely to have depression, anxiety, and alcoholism. This article reviews the many risks associated with psoriatic
arthritis and provides guidance on mitigating these risks.
Keywords: Psoriatic arthritis, Disease-specific risks, Treatment-related risks, Psychological risks, Comorbidities, Quality of
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Background
Psoriatic arthritis (PsA) is a member of the spondyloar-
thropathies (SpA) family of diseases, a diverse group of
chronic inflammatory rheumatic disorders with common
clinical, radiographic, and genetic features [1, 2]. There
are a wide variety of clinical and anatomic characteristics
that distinguish PsA from other chronic rheumatic dis-
eases such as rheumatoid arthritis (RA) and other forms
of SpA [3, 4]. The primary regions affected in patients
with PsA are the peripheral joints, entheses (connective
tissue between tendon or ligament and bone), and axial
sites, often in an asymmetrical pattern, in addition to
psoriasis of the skin and nails [4, 5]. In addition to the
larger joints, the small joints of the fingers, including the
distal interphalangeal (DIP) joints—which are generally
spared by RA—and toes are also typically involved in PsA
[5]. Further, up to 43% of patients with PsA experience
sacroiliitis (inflammation of the sacroiliac [SI] joint) in the
spinal column [6]. Dactylitis (swelling of an entire digit) is
also common in patients with PsA and is a marker of
disease progression [7]. Although PsA is commonly asso-
ciated with the presence of psoriasis, skin disease and joint
inflammation do not always present concurrently [2].
The prevalence of PsA in the United States is 0.25%
[8]. However, the prevalence of PsA in patients with
psoriasis is substantially higher, with approximately 30%
of individuals reported to have both conditions [9]. PsA
is reportedly more common in women than in men
compared with ankylosing spondylitis [5, 10]. Although
it is important to recognize that there may be some
degree of selection bias in this regard (due to conven-
tional wisdom and teaching that women are unlikely to
develop ankylosing spondylitis).
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The differentiation of PsA from RA can be aided by
certain clinical characteristics. Unlike RA, PsA is not as-
sociated with circulating autoantibodies [3, 11]. Patients
with PsA are usually seronegative (absence of circulating
rheumatoid factor) and a negative test for rheumatoid
factor is one component of the ClASsification criteria
for Psoriatic Arthritis (CASPAR) [2, 12]. Additionally,
PsA and RA typically have distinct patterns of inflamma-
tory joint damage, which can be distinguished through
specific clinical and radiological changes. The clinical
pathology of PsA typically presents in the distal interpha-
langeal and axial joints, with an asymmetrical distribution,
whereas RA is primarily symmetrically distributed in the
metacarpophalangeal and wrist joints [3]. However, PsA
may also present as a symmetrical arthropathy or as an
oligoarthropathy. The vascular pathology of PsA is distinct
from RA and is characterized by a hypervascularized
network of elongated, tortuous vessels [3]. Whereas RA
primarily results in bone and cartilage resorption, PsA has
both bone destruction and formation traits [13]. Both
patients with RA and PsA experience erosion that leads to
resorption of cortical bone, but additional formation of
bony spurs is observed along insertion sites of entheses
only in patients with PsA [13].
Like other forms of SpA, susceptibility to PsA is associ-
ated with the human leukocyte antigen B27 (HLA-B27)
gene [2]. The strength of the association between HLA-
B27 and disease susceptibility varies among different SpA
subtypes as well as between ethnic groups and the
presence of HLA-B27 in combination with other major
histocompatibility complex class alleles may influence the
pattern of axial or peripheral disease presentation [14].
The clinical spectrum of PsA is extremely diverse in
both disease severity and tissues affected, and this dis-
order often occurs in conjunction with several associated
comorbidities [4, 15]. The array of symptoms, coupled
with the wide range in severity and disease course, pre-
sents difficult challenges for treatment [16]. Mitigation
of risks associated with the disease itself, its treatment,
and associated comorbidities are all important consider-
ations when managing patients with PsA (Table 1). This
review will discuss and highlight the many risks associ-
ated with PsA, with the aim to help improve awareness
of risks among physicians and to provide guidance in
mitigating these risks.
Disease-specific risks
Risks associated with disease progression
Early diagnosis and treatment of PsA is important be-
cause the disease not only causes functional impairment
over time, but also may increase the risk of mortality in
affected patients [15]. Unfortunately, early detection
methods for PsA remain limited and the disease is often
underdiagnosed due to symptoms going unrecognized [15].
Common initial symptoms include arthritis in the upper
and lower limbs (Table 2).
For proper treatment of PsA, it is necessary to consider
all aspects of the disease, including clinical pathology and
psychological issues [15]. Further, worse outcomes in pa-
tients with PsA are associated with a delay in diagnosis,
disability, and joint damage, whereas male sex and lower
burden of inflammation at presentation were predictors of
improved patient outcomes [17–19]. The presence of spe-
cific HLA alleles can also identify patients likely to sustain
joint damage [19].
Maintaining good functional status is the primary aim
of pharmacologic treatment in patients with PsA. Al-
though the recommended approaches to the diagnosis,
therapy, and follow-up of patients with PsA have changed
numerous times over the past decade, the goal of treat-
ment is remission or, alternatively, low disease activity or
minimal disease activity (MDA) if remission is not attain-
able [20, 21]. Loss of physical functioning directly impairs
Table 1 PsA risk framework
Disease-related risks (including functional concerns)





○ Imaging (X-rays, MRI)




○ Pain Disability Index
○ PsAID
○ Work ability
• Documentation of extra-articular manifestations and/or comorbidities




○ NSAIDs in patients with IBD, CV disease
• Adverse events
○ Liver damage with methotrexate (obese patients
particularly at risk)
• Poor compliance/persistence
○ Reduced efficacy of biologics
• Routine laboratory monitoring with biologics
• Immunogenicity with biologics
Psychosocial risks





• Self-esteem issues (especially in younger patients)
• Social participation
○ PsAID
CV cardiovascular, DASS-21 Depression and Anxiety Stress Scale, IBD
inflammatory bowel disease, MRI magnetic resonance imaging, NSAIDs
nonsteroidal anti-inflammatory drugs, PASI Psoriasis Area and Severity Index,
PsAID Psoriatic Arthritis Impact of Disease, PsAQoL Psoriatic Arthritis Quality of
Life Questionnaire, SF-36 Short-form 36
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patient quality of life (QoL) and results in increased direct
and indirect costs associated with the disease [22]. For ex-
ample, decreased functional status can prevent patients
from performing daily activities of living, such as washing
and dressing [23].
Clinicians should be aware of the relevant extra-articular
manifestations of PsA and its associated comorbidities,
which result in considerable morbidity and mortality [24].
At least 1 extra-articular immune-mediated inflammatory
disease is present in 94.7% of patients with PsA and the
most common of these are psoriasis (94%), uveitis (1.3%),
and inflammatory bowel disease (0.7%) [25]. The extra-
articular manifestations and comorbidities associated with
PsA can also significantly impact QoL and must be
considered in the management of PsA [23].
Risks associated with comorbidities
Patients with PsA have a higher prevalence and incidence of
cardiovascular (CV) disease than the general population
[24, 26]. This increased risk is due to both a higher
prevalence of traditional risk factors such as hypertension,
obesity, diabetes, and hyperlipidemia, and also to nonconven-
tional risk factors, for example, those related to chronic sys-
temic inflammation, including higher levels of C-reactive
protein and erythrocyte sedimentation rate [24, 27]. Interest-
ingly, suppression of inflammation in patients with PsA has
been linked with improvements in surrogate markers of CV
risk, such as increased carotid intima media thickness and
endothelial dysfunction [28]. Further, the presence of meta-
bolic syndrome and insulin resistance, which are also more
common in patients with PsA, are associated with increased
severity of PsA and increased risk of CV disease [29, 30].
These findings suggest that systemic inflammation may play
an important role in driving CV risk in patients with PsA.
Obesity is reported in 35% of patients with PsA and
has been suggested as a potential risk factor for
developing PsA [31, 32]. Obesity may also impact disease
activity and response to therapy, possibly through in-
creased production of inflammatory cytokines [33]. For
instance, irrespective of the kind of therapy used, obesity
is associated a lower probability of achieving MDA and it
is speculated that the chronic pro-inflammatory state, the
biomechanical effect of heavy weight on the joints, and
the altered pain threshold associated with obesity may be
factors responsible preventing achievement of MDA [32].
PsA is associated with diabetes mellitus and the rate of
diabetes mellitus is significantly higher in patients with
PsA than in those with RA (odds ratio 1.56; 95% confi-
dence interval [CI] 1.07–2.28; P = 0.02) [34]. Caution
should be used if prescribing glucocorticoids because
they are associated with an approximately 30% increase
in the risk for developing diabetes mellitus in patients
with psoriasis or PsA [35]. Some dermatologists consider
psoriasis as a contraindication for use of corticosteroids,
due to concerns of converting plaque psoriasis into pustu-
lar psoriasis. However, corticosteroids are still often used
across various practice settings, including dermatology.
A strong relationship has been noted between gastrointes-
tinal (GI) inflammation and joint inflammation in various
forms of SpA [36]. However, the prevalence of inflammatory
bowel disease in patients with PsA is less clearly defined
[24]. Of note, there is a significantly increased risk of Crohn’s
disease in women with psoriasis (relative risk [RR] 3.86, 95%
CI 2.23–6.67) that is further increased in women with both
psoriasis and PsA (RR 6.43, 95% CI 2.04–20.32) [37].
Patients with PsA also suffer from sleep disturbances
and diminished sleep quality that are associated with
generalized pain, anxiety, enthesitis, increased levels of
C-reactive protein, and increased erythrocyte sedimenta-
tion rate [38]. The prevalence of depression in patients
with PsA is 22.2%, compared with 9.6% in patients with
psoriasis alone, and the estimated prevalence in the
general population (9%) [39]. Similarly, the prevalence of
anxiety among patients with PsA is reported as 36.6%,
compared with 24.4% in patients with psoriasis alone [39].
Mitigation of disease-specific risks
Mitigation and evaluation of disease-specific risks is
dependent upon prompt and accurate diagnosis. Currently,
the primary objectives in clinical rheumatology are early
diagnosis and initiation of treatment because diagnostic de-
lays are a significant contributor to poor patient outcomes
[4, 15]. Even short delays (6 months) from symptom onset to
first visit with a rheumatologist have been observed to con-
tribute to development of peripheral joint erosions and worse
long-term physical function [40]. To this end, remission in
PsA has been attributed to early diagnosis and treatment.
Disease-related risks should be evaluated through
good patient history and use of metrics specific to PsA
[41]. These include evaluation of physical function and










Low back pain 13 (26) 31 (17) 0.15
Sacroiliac syndrome 6 (12) 17 (9) 0.59
Neck pain 1 (2) 14 (7) 0.20
Dactylitis 5 (10) 17 (9) 0.79
Arthritis, lower limbs 29 (57) 131 (70) 0.08
Arthritis, upper limbs 27 (53) 106 (57) 0.63
Enthesitis 5 (10) 15 (8) 0.78
(Adapted from: Rojas-Vargas M et al. First signs and symptoms of
spondyloarthritis—data from an inception cohort with a disease course of two
years or less (REGISPONSER-Early). Rheumatology (Oxford). 2009;48(4):404–409)
Significance obtained by the chi-square test for contingency tables
Comparison of REGISPONSER-Early (≤2 years) vs REGISPONSER-Late (>10 years)
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skin involvement, as well as joint examination (tender
joint count, swollen joint count, entheseal assessment).
Additionally, physicians should be aware of the possibil-
ity of PsA when diagnosing and treating patients who
suffer from pre-existing psoriasis. Tracking of metrics
over time should be undertaken to detect whether
medications are ameliorating disease severity. Imaging
may be used for diagnosis and following disease progres-
sion over time [41]. In recent years, magnetic resonance
imaging (MRI) and ultrasonography have been increas-
ingly used for assessment of PsA and have provided
additional information on the pathogenesis of PsA [15].
Treatment with drugs is necessary for patients with
PsA and recommended treatment guidelines tailored to
individual PsA characteristics are shown in Fig. 1 [16].
Although it is important for patients with PsA to remain
active, it is typically not possible to manage disease
symptoms through physical therapy alone.
Treatment-related risks
Risks associated with treatment strategy
Early recognition and intervention with therapy is key to
controlling disease progression in patients with PsA
[15]. The tumor necrosis factor (TNF) inhibitors
etanercept, infliximab, adalimumab, golimumab, and
certolizumab pegol have been shown to improve signs
and symptoms of PsA [42–46]. Additionally, apremilast
(an oral phosphodiesterase-4 inhibitor), abatacept (a T cell
selective costimulation modulator), ustekinumab (an
interleukin- [IL-] 12/23 inhibitor), and secukinumab (an
IL-17A inhibitor) have also shown varying degrees of
efficacy in the treatment of PsA [47–53]. Approved agents
are discussed in more detail in the following section.
Treat-to-target is a therapeutic concept derived from
RA and other diseases [54, 55], which has been proposed
for all forms of SpA [20, 41, 54, 56]. With this approach, a
clear target, such as remission or low disease activity, is
identified and the goal is to sustain this response over
time, with an understanding of the need to treat flares and
keep tight control of disease activity [55]. A universal
definition of the target (e.g., remission, prevention of flare
of disease) is required for the treat-to-target approach
and, in SpA, remission and sustained low disease activity
have been suggested as possible targets [20, 55]. Although
definitions of remission or MDA in SpA have been
proposed, none have been widely accepted or endorsed
and given the multifaceted nature of SpA, a composite of
outcome measures may be most useful [54, 57].
The Tight Control of Psoriatic Arthritis (TICOPA)
trial, an open-label, randomized, controlled study, has
recently provided evidence on the benefit of treating-to-
target in PsA [58]. This study compared treat-to-target
versus standard of care in newly diagnosed patients with
PsA receiving methotrexate (MTX), a combination of
disease-modifying antirheumatic drugs (DMARDs), or
TNF inhibitors. Results from TICOPA demonstrated
that tight control of disease activity using a step-up
dosing regimen to achieve MDA (reviewed and adjusted,
if necessary, every 4 weeks) significantly improved joint
outcomes compared with standard of care (per the
treating physician, reviewed every 12 weeks). After
48 weeks, the odds of achieving an American College of
Rheumatology (ACR) 20% criteria for improvement
(ACR20 response) nearly doubled (odds ratio 1.91; 95%
CI, 1.03–3.55; P = 0.0392) without any unexpected
serious adverse events (AEs) [58].
Risks associated with pharmacologic treatment
The complexities of PsA pathology suggest the need to
identify suitable therapies to address the different combi-
nations of clinical manifestations [21]. Traditional treat-
ments for PsA include nonsteroidal anti-inflammatory
drugs (NSAIDs), steroids, and synthetic DMARDs [59].
NSAIDs are effective for relieving musculoskeletal symp-
toms due to joint inflammation, but have no efficacy on
psoriatic skin lesions and are associated with AEs
including renal toxicity, gastrointestinal toxicity, and the
risk of developing CV events [59]. Traditional DMARD
treatment options for PsA include sulfasalazine and
MTX [16, 59, 60]. There is debate over the efficacy of
MTX and randomized trials have generally been unable
to show efficacy [59, 61, 62]. Additionally, MTX is
ineffective in treating axial inflammation and there is little
evidence to support its use for other symptoms such as
enthesitis [59, 62]. However, in the placebo-controlled
Methotrexate in Psoriatic Arthritis (MIPA) trial (that
showed no benefit with respect to the primary endpoint of
PsA response criteria), treatment with MTX resulted in a
significant improvement over placebo in both patient and
physician global assessments, as well as Psoriasis Area and
Severity Index (PASI) scores at 6 months [61, 62].
Nonetheless, the MIPA authors asserted that their
findings questioned the classification of MTX as a
DMARD in the setting of PsA, with recognition that there
are safety concerns associated with MTX therapy [61]. In
particular, the use of MTX in obese patients may lead to
potential liver damage [63]. Alcohol abuse and the high
prevalence of fatty liver in obese patients may contribute
to the development of liver damage and the presence of
fatty liver can also impede monitoring for liver damage.
Current targeted treatment options approved for PsA
include biologics (TNF inhibitors, ustekinumab, and
secukinumab) and the small molecule apremilast [3, 59].
These therapies are typically recommended for use after
inadequate response to at least one DMARD but early
escalation can be considered, especially for patients with poor
prognostic factors such as raised inflammatory markers or
high active-disease joint counts [16]. For patients who fail a
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biologic therapy, the GRAPPA guidelines provide a
conditional recommendation for switching to a different
biologic agent within a drug class or to a drug with a
different mode of action [16]. While switching TNF inhibi-
tors can be effective, response rates tend to diminish with
successive TNF inhibitor use [64]. There has been investiga-
tion of combining TNF inhibitors with a DMARD to prolong
biologic persistence but a clear benefit of combination
therapy was not observed [65]. There are currently two
biologics (secukinumab and ustekinumab) available for
treatment of PsA with a different mechanisms of action
than TNF inhibition [50, 51, 53]. A concern with all bio-
logic therapies for PsA is an increased risk for infections
and patients should be monitored for the development of
serious infections that would necessitate discontinuation
of treatment until the infection resolves. Reactivation of
tuberculosis has been observed with TNF inhibitors and
patients must be monitored for active tuberculosis while
receiving these agents.
Additionally, response to biologic agents can be limited
by immunogenicity and the development of antidrug
antibodies [66]. Antidrug antibodies have been observed in
29% of patients receiving adalimumab and 21% of patients
receiving infliximab and their presence was significantly
correlated with low drug levels and high levels of disease
activity [66]. This study also reported that MTX signifi-
cantly decreased the prevalence of antidrug antibodies, and
use of MTX should be considered for patients treated with
TNF inhibitors. With secukinumab and ustekinumab,
treatment-emergent antidrug antibodies were reported in
0.2% to 0.3% and 9.3%, respectively, of patients from phase
3 trials [49, 52, 53]. In patients receiving ustekinumab and
MTX, antidrug antibodies were less common (6.4%) than
in those only receiving ustekinumab (12.3%) [52].
Fig. 1 GRAPPA treatment schema for active PsA [16]. Reprinted with permission from: Coates LC et al. Group for Research and Assessment of Psoriasis
and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016;68(5):1060–1071
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Treatment of skin disease associated with PsA can include
phototherapy such as ultraviolet B or oral psoralen followed
by ultraviolet A (PUVA) [67]. PUVA therapy carries an
increased risk of skin cancer compared with other forms of
ultraviolet light treatment and patients receiving this
treatment should be monitored for skin cancer [67, 68].
Risks associated with poor compliance
Patient compliance to therapy is an underlying concern in
the management of PsA. In patients treated with TNF
inhibitors, age has been associated with increased compli-
ance and female sex, comorbidity, and poor clinical condi-
tion at baseline have been associated with decreased
compliance [69]. Poor adherence can reduce therapeutic ef-
ficacy and increase medical costs due to the need for more
aggressive treatments [69, 70]. In general, there is the po-
tential for reduced compliance if a patient cannot observe
their disease directly, although this is less likely in patients
with PsA because skin involvement is more common.
Psychosocial risks
The impact of PsA is not limited to the skin and joints
and patients often experience substantial impairment in
QoL [71]. There is an increased risk of depression and
anxiety in patients with PsA, which can complicate
treatment [71]. Symptoms of depression and anxiety are
associated with low treatment adherence in chronic dis-
eases and can impair the ability of patients to self-manage
[72]. Physicians should remain cognizant of depressive
behaviors such as alcoholism, nonsocial behavior, drug
addiction, and suicide ideation and even though treatment
of PsA can improve symptoms of depression and anxiety,
it is still important for physicians to identify individuals
who would benefit from referral for counseling.
Patients with both PsA and psoriasis experience worse
QoL than those with only psoriasis [73]. Additionally, this
difference in QoL was not due to differences in other
comorbidities between patients with and without joint in-
volvement [73]. Collectively, further efforts should be made
by physicians to identify patients with PsA who should be
referred for counseling as well as to monitor changes in
these psychosocial issues over the course of treatment.
Conclusions
Among patients with PsA, a major emphasis of compre-
hensive care should be aimed at mitigating risks and im-
proving physical health-related QoL. As outlined above,
this may be achieved by early diagnosis, prevention of
disease progression, treatment of PsA-associated physical
morbidity, mitigation of treatment-related risk, and treat-
ment of associated medical comorbidity. Various agents,
including newer biologics, have approved indications for
use in the PsA population—providing the clinician and
patients with choices of agents based on their specific
disease symptoms. Overall, management of patients with
PsA is complex and requires the adoption of a more
patient-focused multidisciplinary approach.
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